ALK and non-small cell lung carcinoma: The phase III trial KEYNOTE‐189, demonstrated that pembrolizumab addition increased overall survival (OS) by 11.3 months compared with chemotherapy, establishing immunologic addition to platinum‐dual chemotherapy as first‐line therapy in metastatic NSCLC, but excluded patients with EGFR or ALK mutations.16, 17